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Type II germ cell tumors arise after puberty from a germ cell that was incorrectly pro-
grammed during fetal life. Failure of testicular germ cells to properly differentiate can
lead to the formation of germ cell neoplasia in situ of the testis; this precursor cell invari-
ably gives rise to germ cell cancer after puberty. The Nodal co-receptor Cripto is expressed
transiently during normal germ cell development and is ectopically expressed in non-
seminomas that arise from germ cell neoplasia in situ, suggesting that its aberrant expres-
sion may underlie germ cell dysregulation and hence germ cell cancer. Here we investi-
gated methylation of the Cripto promoter in mouse germ cells and human germ cell
cancer and correlated this with the level of CRIPTO protein expression. We found hypome-
thylation of the CRIPTO promoter in undifferentiated fetal germ cells, embryonal carci-
noma and seminomas, but hypermethylation in differentiated fetal germ cells and the
differentiated types of non-seminomas. CRIPTO protein was strongly expressed in germ
cell neoplasia in situ along with embryonal carcinoma, yolk sac tumor and seminomas.
Further, cleaved CRIPTO was detected in media from seminoma and embryonal carcinoma
cell lines, suggesting that cleaved CRIPTO may provide diagnostic indication of germ cell
cancer. Accordingly, CRIPTO was detectable in serum from 6/15 patients with embryonal
carcinoma, 5/15 patients with seminoma, 4/5 patients with germ cell neoplasia in situ cells
only and in 1/15 control patients. These findings suggest that CRIPTO expression may be a
useful serological marker for diagnostic and/or prognostic purposes during germ cell can-
cer management.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.In Situ; CH, choriocarcinoma; dcp, days post coitum; ELISA, enzyme-linked immunosorbent
ing; GCC, germ cell cancer; NS, non-seminoma; SE, seminoma; TE, teratoma; YST, yolk sac
l (L.H.J. Looijenga).
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ochemical Societies. Published by Elsevier B.V. All rights reserved.
M O L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 5 2 6e5 3 7 5271. Introduction of the Cripto promoter during normal fetal germ cell develop-Testicular germ cell cancers (GCCs), also known as Type II
germ cell tumors (Oosterhuis and Looijenga, 2005), account
for w60% of all malignancies in men aged 20e40 (Adami
et al., 1994; van de Geijn et al., 2009). The cell of origin or ‘can-
cer stem cell’, germ cell neoplasia in situ (GCNIS, according to
the newest WHO classification, 2016), previously known as
carcinoma in situ (CIS) and intratubular germ cell neoplasia
unclassified (IGCNU), is considered to be an embryonic germ
cell that has failed to differentiate into a pre-
spermatogonium during development (Skakkebaek et al.,
1987). Although GCNIS may be present before birth, it does
not transform into GCC until after puberty when tumor pa-
thology is classified into seminoma (SE) and non-seminoma
(NS) (Sonne et al., 2009; van de Geijn et al., 2009). SE is charac-
terized by fetal germ cell-like expression profile, and NS com-
prises both highly pluripotent/undifferentiated tumors
(embryonal carcinoma; EC) and differentiated tumors: yolk-
sac tumor (YST); choriocarcinoma (CH); teratoma (TE) and
combinations of these.
The ‘fetal origins hypothesis’ of GCNIS predicts develop-
mental pathways that control fetal germ cell pluripotency/dif-
ferentiation contribute to their malignant potential. We
recently discovered that the TGFb signaling molecule Nodal
and its obligate receptor Cripto are expressed at a critical point
during fetal XY germ cell development inmice and that Nodal/
Cripto signaling is active, apparently acting to maintain plu-
ripotency and oppose differentiation (Spiller et al., 2012). We
also found that Nodal/Cripto signaling is ectopically activated
in NS and we therefore hypothesize that ectopic activation of
Nodal signaling, or failure to silence it, contributes to GCC for-
mation (Spiller et al., 2013).
Nodal, a member of the TGFb family, signals by binding to
Activin receptors in the presence of the receptor Cripto (also
known as teratocarcinoma derived growth factor 1; Tdgf1).
Nodal signaling is absent in normal adult tissues, but is critical
for patterning events during embryogenesis (Shen, 2007).
Cripto is also essential during embryogenesis, and plays addi-
tional roles in stem cell self-renewal and pluripotency in hu-
man embryonic stem cells (Bianco et al., 2010; Wei et al.,
2005). Its continuous activation is associated with initiation
or progression of cancer in many tissues including skin,
pancreas, intestine, breast, bladder and brain (Klauzinska
et al., 2014). As a cell-surface receptor for Nodal, Cripto must
remain tethered to the cell membrane via its glycosylphos-
phatidylinositol (GPI) anchor at its carboxy terminal
(Watanabe et al., 2007b). Cleavage of Cripto at the GPI anchor
by GPI-phospholipase D produces a shorter, biologically active
form of Cripto that can promote endothelial cell migration, in-
dependent of Nodal signaling (Watanabe et al., 2007a). Detec-
tion of cleaved Cripto in serum has been identified as a
promising diagnostic for breast, colon and brain cancer
(Bianco et al., 2006; Pilgaard et al., 2014).
Hypomethylation of oncogenes and hypermethylation of
tumor-suppressor genes are commonly seen in cancer, there-
fore it is possible that dysregulation of Cripto expression in
GCC may reflect aberrant methylation of regulatory se-
quences. In this study we investigated the methylation statusment in mice and contrasted this to human GCC. We also
assessed Cripto protein expression in GCNIS and GCC of
different histologies. Lastly we used ELISA to quantitate levels
of Cripto protein present in conditioned media from GCC cell
lines and serum from patients with GCC.2. Materials and methods
2.1. Mouse strains
Protocols and use of animals in these experiments were
approved by the Animal Ethics Committee of the University
of Queensland. Embryos were collected from timed matings
of the CD1 strain and Oct4DPE:eGFP (OG2) strain (Szabo
et al., 2002), with noon of the day on which the mating plug
was observed designated 0.5 days post coitum (dpc).
2.2. Gonadal collection, germ cell isolation
Gonadswithoutmesonephros were dissected at 11.5e17.5 dpc
from CD1 embryos. At 11.5 dpc embryos were genotyped by
PCR for genetic sex (McFarlane et al., 2013); later stages were
sexed visually by gonad morphology. For each stage three
pools of 4 gonads were processed for qRT-PCR. For germ
cell isolation, sexed gonadal tissue was collected from Oct4D
PE:eGFP matings. Tissue was dissociated and germ cell
(GFPþ) populations isolated by fluorescence-activated cell
sorting (FACS) using a FACSAria Cell Sorter (BD Biosciences).
For each sex and timepoint approximately 100,000 cells were
collected and processed for methylation profiling.
2.3. Cell line culture and 5-azacytidine treatment
TCam-2 and JKT-1 were maintained in RPMI (Life Technolo-
gies), and NT2 and TERA-1 cells in DMEM (Life Technologies)
with the addition of 10% fetal calf serum (GE Healthcare Life
Sciences, HyClone Laboratories), 100 U/ml penicillin and
100 ug/ml streptomycin in a humidified 5% CO2, 37 C incu-
bator. Treatment with 5-azacytidine (AG scientific) was used
at a final concentration of 10 mM (Wermann et al., 2010).
2.4. Human GCC samples
Use of tissue samples for scientific reasons was approved by
an institutional review board (MEC 02.981 and CCR2041) in
The Netherlands and by the Human Research Ethics Commit-
tee at the University of Queensland. Samples were used ac-
cording to the “Code for Proper Secondary Use of Human
Tissue in The Netherlands” developed by the Dutch Federa-
tion of Medical and Scientific Societies (FMWV) (Version 2, up-
date 2011). Tissues were collected as described (Looijenga
et al., 2003) and diagnosed according to WHO standards by
an experienced pathologist (J.W Oosterhuis, ErasmusMC, Rot-
terdam, The Netherlands). The testicular parenchyma sam-
ples investigated have been described previously
(Mosselman et al., 1996) and comprised of tissue micro-
arrays as well as single biopsies. Samples (paraffin blocks,
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dam, The Netherlands and selected to exemplify different his-
tological subtypes.
2.5. Quantitative RT-PCR
Total RNA was extracted (RNeasy kit; Qiagen) and cDNA
generated (High capacity cDNA Reverse Transcription kit;
Applied Biosystems) according to manufacturers’ instruc-
tions. Taqman probes (Applied Biosystems) used were: mouse
(Tbp; Mm00446973_m1, Cripto/Tdgf1; Mm00783944_g1) and hu-
man (TBP; Hs00427621_m1, CRIPTO/TDGF1; Hs02339499_g1,
NODAL; Hs00415443_m1, LEFTY1; Hs00764128_s1, LEFTY2;
Hs00745761_s1, SOX2; Hs01053049_s1, SOX17; Hs00751752_s1,
GFD3; Hs00220998, DNMT3L; Hs01081364_m1). Relative tran-
script abundance was calculated using the 2DCT method. Er-
ror bars represent S.E.M calculated from independent
biological replicates.
2.6. Methylation profiling e mouse germ cells
DNA was extracted (Qiagen, DNeasy kit) from freshly isolated
germ cells and bisulfite-treated (Zymo Research, EZ DNA
Methylation Kit). Between 2 and 4 ng of bisulfite-treated and
untreated (control) DNA was subjected to two rounds of PCR
amplification with Hot-start Taq DNA Polymerase (NEB) (con-
ditions described in Supplementary Table 1). The first amplifi-
cation of 35 cycles used flanking primers in a 25 ml reaction.
Subsequently 1 ml of this reaction was subjected to a further
35 cycles using nested primers. PCR products were gel puri-
fied, cloned into pGEM-T Easy (Promega) and 10e15 clones
sequenced using T7 and T3 primers at the Australian Genome
Research Facility (Brisbane, Australia).
2.7. Methylation profiling e GCC cell lines and tumor
samples
DNAwas extracted from cell lines and tumor biopsies accord-
ing to manufacturer’s instructions (Qiagen, DNeasy kit). DNA
was bisulfite-treated (Zymo Research, EZ DNA Methylation
Kit) and 2.5 mg of bisulfite treated and untreated (control)
DNAwas subjected to one round of PCR amplification of 40 cy-
cles with Zymo Taq DNA Polymerase (Zymo Research) (condi-
tions described in Supplementary Table 1). PCR reactions were
subjected to ExoSAP-IT PCR clean-up protocol (Affymetrix).
For direct sequencing, 5 ml of the purified PCR product was
used with the ABI Prism BigDye Terminator sequencing kit
(Applied Biosciences, v1.1) with forward and reverse primers.
For colony sequencing, 1 ml of the PCR product was cloned into
the TOPO-TA vector (Life Technologies) and 10e15 clones
sequenced using the ABI Prism BigDye Terminator sequencing
kit (Applied Biosciences, v1.1) with M13 primer.
2.8. Immunohistochemistry
Paraffin sections (3 mm) of previously characterized tumors
were deparaffinised and heated under pressure to 1.2 bar in
0.01 M Tris, 0.001 M EGTA, pH 9.0. Slides were blocked with
Avidin and Biotin solution (Vector Laboratories) and incubated
with monoclonal anti-CRIPTO antibody (1:10000;commissioned from Abmart; raised against epitope sequence
FPQAFLPG) in 0.2%BSA/PBS overnight at 4 C. Biotinylated Rab-
bit anti-mouse antibody (1:150; Dako E413) was incubated for
30 min at RT followed by incubation with Avidin-Biotin-HRP
complex (Vector Laboratories) for 30 min and staining visual-
ized with DAB reagents (Vector Laboratories). Slides were
counterstained with haematoxylin and mounted.
2.9. Western blotting
NT2 cells were lysed in RIPA buffer and sonicated, run on a
10% SDS-PAGE gel, transferred to PVDF membrane then
blocked/probed in 5% skim milk/PBS. Primary antibodies
(anti-CRIPTO; Abmart 8295; 1:10000, TUBA1A; Sigma T5168;
1:1000) were incubated overnight at 4 C and secondary anti-
bodies (mouse-HRP; Sigma a8924; 1:2000) for 1 h at RT. Detec-
tion was performed using ECL (BioRad) and imaged using
BioRad ChemiDoc.
2.10. Cripto ELISA
Human Cripto-1 DuoSet ELISA Development kit (DY145; R&D
Systems) was used as per manufacturer’s instructions. Cell
culture media was diluted 1:5 with 0.1% BSA/PBS. Complete
media diluted 1:5 in 0.1% BSA/PBS with standards was used
as the control to generate the standard curve for interpolation.
For serum analysis, whole serum was diluted 1:2 in 0.1% BSA/
PBS and standards spiked into control serum diluted 1:2 in
0.1% BSA/PBS to generate the standard curve for interpolation.
All standards and unknowns were assayed in duplicate. Opti-
cal density was determined using a microplate reader (Bio-
Rad) with the 570 nm reading subtracted from the 450 nm
reading. Duplicate readings for each sample were averaged
and the zero standard optical density subtracted from this
value. Prism software was used to generate a four-parameter
logistic curve-fit and unknown values were interpolated to
give the final CRIPTO concentration. For assessment of our
commissioned CRIPTO antibody (Abmart) the ELISA assay
was performed exactly as per manufacturer’s instructions
with the exception that the R&D Systems capture antibody
was replaced with the Abmart CRIPTO antibody at a concen-
tration of 5 ug/ml. Recombinant CIRPTO standard range was
0e4000 ng/ml.3. Results
3.1. Cripto promoter methylation in mouse fetal germ
cells
Because we have shown that Cripto is expressed for a short
time in fetal germ cells but is ectopically expressed in GCC
(Spiller et al., 2012), we wanted to investigate the mechanism
by which Cripto expression is properly silenced under normal
conditions using themousemodel. We began by investigating
methylation of CpG dinucleotides in the promoter region,
since male germ cells are known to undergo genome-wide
remethylation from 13.5 to 18.5 days post coitum (dpc) in
mice (La Salle et al., 2004; Western et al., 2010). Using Methyl
Primer Express software (v1.0, Applied Biosystems) we
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CpG site-content. Region 1 is 1383 bp upstream of the tran-
scription start site (15 CpG sites) and Region 2 spans the tran-
scription start site (18 CpG sites) (Figure 1A).
To assess methylation specifically in germ cells, we iso-
lated male and female (control) germ cells from Oct4DPE:eGFP
mouse embryos (Szabo et al., 2002) using FACS at 13.5 dpc
(Cripto is expressed in the male) and at 17.5 dpc (expression
has declined in the male; Figure 1B, Supplementary
Figure 1). Bisulfite-treated DNA was subjected to PCR amplifi-
cation of the two CpG regions before cloning and sequence
analysis. We found that XX (female) germ cells displayed
increased methylation in Region 1 from 13.5 to 17.5 dpc (6%e
24% average methylation) while methylation of Region 2
remained unchanged (27% both timepoints; Figure 1C).
Conversely, XY (male) germ cells displayed an increase in
methylation of Region 2 from 13.5 to 17.5 dpc (22%e56%),
whilst CpG sites in Region 1 remained unmethylated at both
timepoints (1% and 0%) (Figure 1C). These data indicate that
methylation of CpG sites in Region 2 correlates with declining
Cripto expression male germ cells.Figure 1 e Bisulfite analysis of CpG methylation in the promoter region of C
has two CpG islands in the proximal promoter region: Region 1 at position
contains 18 CpG sites. (B) Cripto is expressed maximally in male gonads at 1
female gonads at 11.5 dpc before becoming downregulated by 12.5 dpc in th
11.5e17.5 dpc. Expression normalized to Tbp; error bars represent ±S.E.M; n
are shown for purified male and female germ cells at 13.5 and 17.5 dpc. Fo3.2. CRIPTO promoter methylation in human GCC
We next investigated whether methylation of the human
CRIPTO promoter might also correlate with levels of gene
expression in the various GCC specimens, using a combina-
tion of direct- and colony-bisulfite sequencing. The human
CRIPTO proximal promoter contains two CpG regions that
contain 14 and 7 CpG sites, respectively (Figure 2A). These re-
gions have previously been shown in the EC cell line NT2/D1 to
be differentially methylated according to expression level and
potential malignancy of these cells (Watanabe et al., 2010).
Gene expression of CRIPTOwas highest in EC and YST, with
low transcript expression detectable in SE, TE and CH samples
(Figure 2B). By colony sequencing, CH and TE (low CRIPTO
expression) displayed high levels of methylation (average
75% and 72%, respectively) in both regions (Figure 2C,D).
Conversely, in EC, which displays high levels of CRIPTO
expression, methylation levels were relatively low (20%;
Figure 2E). In contrast, despite high expression of CRIPTO in
YST, both regions remainedmoderately-to-highly methylated
(67%; Figure 2F). Further, in SE, which expresses low levels ofripto in 13.5 and 17.5 dpc germ cells. (A) The mouse Cripto promoter
-1383 e 642 contains 15 CpG sites. Region 2 at positionL50 e D50
2.5 dpc and has declined by 14.5 dpc. Expression is similar in male and
e female. qRT-PCR of pooled gonad-only male and female samples at
[ 3. (C) Methylation (expressed as % methylation) for each CpG site
r each sample ‡10 clones were sequenced.
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Figure 2 e Bisulfite analysis of GpG methylation in the promoter region of CRIPTO in GCC pathologies. (A) The human CRIPTO promoter has
two CpG islands in the proximal promoter region: Region 1 at positionL800 toL662 contains 13 CpG sites. Region 2 at positionL225 toL84
contains 7 CpG sites. (B) qRT-PCR analysis of CRIPTO expression (Log2 scale) in normal testis (control) and NS and SE samples; n[ 5, 4, 9, 10,
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Figure 3 e Immunohistochemistry for CRIPTO expression (brown
staining) in EC (A), YST (B), SE (C), TE (D) and GCNIS (E)
pathologies, counterstained with haematoxylin. Images are
representative of ‡8 biopsies analyzed for each subtype at a
magnification of both 100 and 2003 (left and right images,
respectively).
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Figure 2G). These results were confirmed by direct sequencing
(Figure 2CeG). As a negative control we included the JKT-1 cell
line that is hypothesized to originate from a more mature
germ cell (spermatocyte) (de Jong et al., 2007) and is negative
for CRIPTO expression (Supplementary Figure 2A). In accor-
dance with the lack of CRIPTO expression, JKT-1 cells were
found to be highly methylated using colony sequencing
(80%; Figure 2H). Together, these data indicate that hyperme-
thylation of the Cripto promoter is associated with low gene
expression in CH and TE and hypomethylation is associated
with high gene expression in EC. This correlation does not
hold true for SE and YST, which presumably utilize other
methods (or methylated regions) for gene regulation.
We also included several GCC cell lines in the methylation
analysis. CRIPTO was expressed most strongly at the mRNA
level in the TERA-1 and NCCIT cells, at lower levels in NT2,
TCam2 and 833 KE cells, and was undetectable in control
JKT-1 cells (Supplementary Figure 2A). The EC (833 KE, NT2,
NCCIT, TERA-1) and SE (TCam-2) cell lines, which express
CRIPTO at varying levels, all showed lowmethylation by direct
sequencing, although generally higher methylation in Region
2 compared to Region 1 (Supplementary Figure 2B).
Lastly, we performed in vitro demethylation of the genome
by 5-azacytidine treatment of NT2 and TCam2 cell lines to
observe the effect on CRIPTO expression. Although both cell
lines display low levels of CRIPTO promoter methylation orig-
inally, upon 5-azacytadine treatment methylation was
reduced even further in both regions, assessed by direct
sequencing (Supplementary Figure 3A). Interestingly, qRT-
PCR analysis revealed that CRIPTO mRNA expression was
slightly reduced 48 h post treatment in both NT2 and TCam2
cells lines (0.5 and 0.2 fold, respectively; Supplementary
Figure 3B). Becausemany genes have altered expression under
such artificial conditions we also investigated expression of
NODAL and the negative regulators of NODAL/CRIPTO
signaling: LEFTY1 and LEFTY2 (Supplementary Figure 3B). We
found NODAL expression to be greatly induced by demethyla-
tion in NT2 cells, and slightly reduced in TCam2 cells. Expres-
sion of both inhibitors LEFTY1 and LEFTY2 were induced
robustly in both cell lines. We also assessed expression of plu-
ripotency markers SOX2, SOX17 and GDF3 (Supplementary
Figure 3B). Concordant with other studies, SOX17 expression
was not significantly altered under the demethylating condi-
tions in either cell line (Wermann et al., 2010) and SOX2 and
GDF3 were decreased in NT2 cells (Biswal et al., 2012). The
DNA methyltransferase DNMT3L, was induced in both cell
lines under these conditions, as also reported previously in
TCam2 cells (Wermann et al., 2010). These results suggest
that under the artificial condition of induced genome-wide
demethylation, CRIPTO expression follows expression of other
key pluripotency markers, consistent with its role in stem cell
self-renewal and maintenance (Bianco et al., 2010; Biswal
et al., 2012; Wei et al., 2005).7, 10. Methylation for each CpG site is shown for CH (C), TE (D), EC (E
graphs represent colony sequencing of ‡10 clones of one sample, each bar
sequencing of 2e4 different tumor samples is presented as circles at each C
represent a methylated site and half-filled circles represent heterogeneity o3.3. CRIPTO expression in GCNIS and GCC
We next investigated CRIPTO protein expression in the same
tissues and cell lines as investigated for methylation and
mRNA expression. Based on qRT-PCR data (Figure 2A) we ex-
pected strong expression of CRIPTO in EC and YST, and low
or no expression in SE and TE biopsies. We commissioned
the production of a mouse monoclonal antibody raised), YST (F) SE (G) and JKT-1 control cell line (H). For each sample,
representing one CpG site (expressed at % methylation). Direct
pG site. Open circles represent unmethylated site, closed circles
f methylation at this site within a given sample.
Figure 4 e (A) Immunohistochemistry for CRIPTO expression in
JKT-1, TCam-2, TERA-1 and NT2 cell lines (B) CRIPTO
concentration (ng/mL) assessed by ELISA in cell culture media
collected from cell lines NT2 (range: 2.85e30.35), TERA-1 (range:
1.58e18.28), TCam2 (range: 0.78e4.19) and JKT-1 (range: 0.0e0.0)
at varying confluences (ranging 10e100%). Error bars represent
±S.E.M; n [ 13,6,6,6.
Figure 5 e CRIPTO concentration (ng/mL) assessed by ELISA in
patient serum of control (no testicular malignancy), SE, EC, YST,
GCNIS-only, CH and TE pathologies. Error bars represent ±S.E.M;
n [ 15,15,15,3,5,1,5.
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 5 2 6e5 3 7532against part of the signal peptide of CRIPTO and verified that
this antibody recognizes a single band in NT2 cells at the pre-
dicted molecular weight of 26 kDa (Supplementary Figure 4A).
Further, this antibody outperformed the commercial R&D Sys-
tems capture antibody in recognizing recombinant CRIPTO in
a sandwich ELISA assay (Supplementary Figure 4B). By immu-
nohistochemistry we detected strong reactivity in EC and YST
(Figure 3A,B). Despite a lower transcript abundance, we
detected CRIPTO protein uniformly, but at lower intensity, in
SE (lymphocytes were negative) (Figure 3C). In the differenti-
ated GCC histology TE we found positive staining in small re-
gions of differentiated cells, although large areas of tumor
were negative for CRIPTO (Figure 3D).
We also investigated whether CRIPTO was expressed in
GCNIS cells. Consistent with previous results showing
elevated CRIPTO expression in testis biopsies containing
GCNIS (Spiller et al., 2012), strong expression of membrane-
bound CRIPTO was detected in GCNIS cells (verified by Pathol-
ogist J.W. Oosterhuis; Figure 3E). In normal testicular tissue,
membranous CRIPTO was detectable only in spermatogonial
stem cells (verified by J.W. Oosterhuis; Supplementary
Figure 5A). Some positive staining was detected in nuclei of
spermatocytes: we presume that this represents non-specific
binding as is seen for various antibodies (unpublished obser-
vations). Spermatids and all interstitium were negative for
CRIPTO. Negative controls omitting primary antibody showed
no staining (Supplementary Figure 5B).
3.4. Soluble CRIPTO detection in GCC cell line media
Although GPI-anchored to the cell membrane, CRIPTO can be
cleaved at this site and signal as a soluble ligand (Watanabe
et al., 2007a, 2007b). The presence of soluble CRIPTO has
been reported in the serum of patients with breast cancer, co-
lon cancer and glioblastomamultiforme brain tumors (Bianco
et al., 2006; Pilgaard et al., 2014) which suggests that it may be
detectable, similarly, in serum of patients with GCC. Initially
we investigated this possibility in GCC cell lines. By immuno-
histochemistrywe foundCRIPTO expressed in TCam2, TERA-1
and NT2 cell lines, but not JKT-1 control cells (Figure 4A).
Although TERA-1 and NT2 cells uniformly expressed CRIPTO,
individual TCam2 cells displayed variable expression (absent
to strong). We next evaluated the concentration of CRIPTO
present in themedia of each of these cell lines using sandwich
ELISA. CRIPTO was undetectable in JKT-1 culture media
(Figure 4B), consistent with the negative immunohistochem-
istry and qRT-PCR data (Supplementary Figure 1A). Highest
average levels of cleaved CRIPTO were detected in media of
the EC cell lines NT2 (11.7 ng/ml) and TERA-1 (8.7 ng/ml),
and lower levels in SE cell line TCam2 (1.4 ng/ml) (Figure 4B).
Levels of expression varied depending on confluency of the
cells (ranging 10e100%), which is reflected in the range of
values detected.
3.5. Soluble CRIPTO detection in GCC patient serum
Having found CRIPTO detectable in GCC by immunohisto-
chemistry (Figure 3) we next assessed serum of patients
with various GCC pathologies (Figure 5 and Table 1). Using
ELISA, only one of 15 control patients (6.6%) generated
Table 1 e CRIPTO concentration in serum.
Patient group No. Positive samples/total CRIPTO concentration (ng/mL) Statistics
Mean (SD) Range Pa Pb
Control 1/15 0.77 (2.97) 0.0e11.48 e e
SE 5/15 7.61 (24.22) 0.0e94.36 0.1433 0.0437
EC 6/15 3.66 (11.59) 0.0e44.98 0.0695 0.0178
YST 1/3 1.52 (2.63) 0.0e4.56 0.3137 0.1875
GCNIS-only 4/5 0.59 (0.67) 0.0e1.63 0.0049 0.0016
TE 0/5 e e e e
CH 0/1 e e e e
a ManneWhitney U test of patient group versus control.
b ManneWhitney U test of patient group versus control excluding positive outlier.
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ular malignancy at biopsy, but presented with some testicular
abnormality such as testicular torsion or epididymitis. Inclu-
sion in this ‘control’ group did not exclude the possibility
that other somatic malignancies may have been present
without our knowledge at the time of serum collection). High-
est levels of CRIPTOwere detected in SE samples, of which 5 of
15 (33%) were positive and had an average value of
7.6  24.2 ng/ml. The large standard deviation in this group
is accounted for by one sample, of unknown clinical stage,
that generated an unusually high reading of 94.36 ng/ml of
CRIPTO. In EC serum samples, CRIPTO was detected in 6 of
15 (33%) at an average concentration of 3.6  11.6 ng/ml. One
of 3 YST samples (33%) was positive (average 1.5  2.6 ng/
ml). Lower levels of CRIPTO were detected in 4 of the 5
GCNIS-only samples (80%). The GCNIS-only group had an
average concentration of 0.6  0.7 ng/ml and was distinct, in
a statistically significant manner, from the control group.
The 5 TE and 1 CH serum samples were negative for CRIPTO
expression in this assay. When these data were analyzed
against the control group omitting the outlying sample (high
CRIPTO concentration of 11.5 ng/ml), we found that EC, SE
and GCNIS-only groups were significantly distinct from con-
trol (Table 1).4. Discussion
Previous studies in mice have established a role for Nodal/
Cripto signaling in the maintenance of germ cell pluripotency
during a short window of germ cell development (Spiller et al.,
2012). This period of development is believed to correspond to
a window of vulnerability for germ cell transformation into
GCNIS, the common precursor of all GCC. The finding that
CRIPTO is relatively highly expressed in GCC (Baldassarre
et al., 2001; Spiller et al., 2012) suggests that embryonic CRIPTO
expression may fail to extinguish during malignant transfor-
mation. In the present study we found that epigenetic factors
may be responsible for this aberrant expression during adult
life. We also provide proof-of-principle that detection of
cleaved CRIPTO protein in serum might be a useful avenue
for prognostic and/or diagnostic application to GCC.
As expected, we found that methylation was highest in
mouse germ cell populations where Cripto expression is low.
Of the two regions analyzed in fetal germ cells, it appearsRegion 2, spanning the transcription start site, is more impor-
tant: CpG sites in Region 2 became hypermethylated in XY
germ cells as expression declined, while the more distal CpG
sites (Region 1) remained hypomethylated at both timepoints.
There was little change to methylation in XX germ cells in
either region over time, likely because they do not undergo
genome-wide remethylation but, rather, enter meiosis (La
Salle et al., 2004;McLaren, 2003;Western et al., 2010).We spec-
ulate that the hypomethylation of Region 1 is responsible for
allowing the transient expression of Cripto in XY germ cells,
and further, that hypermethylation of this site may be a
meiosis-specific methylation pattern in XX germ cells that
helps prevent expression of Cripto that might otherwise
disrupt meiosis. Methylation analysis of sexed, 11.5 dpc
germ cells before sex-specific gene expression begins,
although technically challenging, would shed light on these
possibilities.
Similarly to mouse, the human CRIPTO promoter has two
regions enriched for CpG sites (Bianco et al., 2013; Watanabe
et al., 2010). In our cell line analysis, we find both regions
generally hypomethylated in SE and NS cell lines that express
CRIPTO, regardless of relative expression levels, and both re-
gions hypermethylated in the control cell line that is negative
for CRIPTO expression. These results concur with recent find-
ings using DNA methylation PCR for Region 2 of CRIPTO in
which <10% of this promoter region was found to be methyl-
ated (Bianco et al., 2013). In order to link methylation of these
regions to CRIPTO gene expression,Watanabe et al. (2010) per-
formed retinoic acid-induced DNA methylation in the EC cell
line NT2/D1 and showed that time-dependent methylation
of the sameCpG regionswe investigated, correspond to reduc-
tion in CRIPTO expression. Further, they showed that differ-
ences in methylation of CpG Region 1 correspond to gene
expression in this cell line, supporting the claim that methyl-
ation is partially responsible for CRIPTO gene regulation
(Watanabe et al., 2010). Here we tested the opposite approach
of in vitro genome wide demethylation using 5-azacytadine in
NT2 and TCam2 cells and found that under these conditions
CRIPTO expression was slightly decreased post-treatment.
Although somewhat surprising, this could be due to a combi-
nation of factors, including that these regions are already suf-
ficiently hypomethylated or that upregulation of negative
inhibitors of CRIPTO/NODAL signaling such as LEFTY1, -2
(andmany others that we did not test for) could have negative
feedback on CRIPTO expression. In addition to these
MO L E C U L A R O N C O L O G Y 1 0 ( 2 0 1 6 ) 5 2 6e5 3 7534possibilities it is also possible, and likely, that CRIPTO falls
within the complement of classic ‘pluripotency’ factors that
become downregulated under the artificial in vitro conditions
of global demethylation (along with NANOG, SOX2, GDF3 and
MYC target genes; (Biswal et al., 2012)).
In the GCC samples, we found a clear correlation between
CRIPTO promoter hypermethylation and low CRIPTO expres-
sion in TE and CH tumor subtypes, and vice versa for EC. These
correlations were not found for YST and SE. Instead, in YST
samples (which display high levels of CRIPTO expression),
we found high levels of methylation in Region 1 of the CRIPTO
promoter, while Region 2 showed moderate levels of methyl-
ation. However, as YST is known to display high levels of
global methylation (Amatruda et al., 2013; Furukawa et al.,
2009), it is possible that the moderate level of methylation in
Region 2 is sufficient for gene transcription, although it is
likely that additional mechanisms are involved. Similarly,
for SE, the hypomethylation observed in our findings is seem-
ingly contrary to low CRIPTO expression, but is consistent with
the global hypomethylation that characterizes this GCC sub-
type (Netto et al., 2008; Smiraglia et al., 2002; Wermann
et al., 2010). It is possible that modest methylation of Region
1 is sufficient to suppress gene transcription in this genomic
environment of global hypomethylation.
Exactly how a GCNIS cell transforms into the two distinct
tumor types, SE and NS, which are characterized by hypo-
and hypermethylation, respectively, is unknown. This issue
is of interest because of the different sensitivity of the SE
and NS elements to irradiation and cisplatin-based chemo-
therapy. GCNIS cells, like SE, exhibit global hypomethylation,
akin to their fetal germ cell precursors, so de novomethylation
is thought to be largely responsible for establishment of the
methylation profile in the overt tumor (Almstrup et al., 2010;
Netto et al., 2008; Wermann et al., 2010). Based on our fetal
germ cell data, we might expect CRIPTO Region 1 to be
completely hypomethylated and Region 2 to have variable
methylation in a given GCNIS cell. Indeed it has been shown
that differing levels of CRIPTO expression and methylation
in the NT2 human EC cell line correlate with malignancy po-
tential of these cells (Watanabe et al., 2010). It will beFigure 6 e Schematic of CRIPTO/NODAL/GDF3 signaling (A) and the
embryonic stem cells and the subtypes of GCC (B). Symbols represent pos
expression (L/D).interesting to investigate whether individual GCNIS cells ex-
press CRIPTO at varying levels, and whether methylation of
Region 1 may be predictive of a GCNIS cell that will give rise
to EC (hypomethylation) or SE (moderate levels of
methylation).
We found in our cell line analysis that protein expression
of CRIPTO, detected by immunohistochemistry, was compara-
ble between NT2 and TERA-1 cells, despite lower gene expres-
sion in NT2 cells. This discrepancy is likely the result of
different confluency of the cells when assayed for RNA and
protein, as confluency was seen to greatly affect levels of sol-
uble CRIPTO detected in media using the ELISA assay. This is
consistent with a report from Watanabe et al. (2010) that see
CRIPTO expression decline in NT2/D1 cells at confluency.
Similarly, although we expected strong protein expression of
CRIPTO in EC and YST, based on other reports and our own
gene expression data, we were surprised to find that it could
also be detected in SE and small regions of TE biopsies, where
gene expression is overall low. However, expression of CRIPTO
in GCNIS makes it extremely likely that it would also be
expressed in SE, as these two cell types share similar expres-
sion profiles (Almstrup et al., 2005). We don’t consider it likely
that our antibody is detecting an unspecific target in SE based
on the Western blot results and the fact that our immunohis-
tochemistry data was corroborated by the independently-
tested antibodies in the sandwich ELISA, which detected
CRIPTO protein in the SE cell line TCam2 and in serum of pa-
tients with SE. This surprising finding of low gene expression
with high protein detection is not unique, and for example has
also reported for GDF3, in which the transcript is predomi-
nantly expressed in EC and YST but the protein is also
detected in GCNIS and SE (Gopalan et al., 2009; Korkola et al.,
2006). This similarity is of interest as GDF3 is a known ligand
for CRIPTO and is one of the stem cell genes in the 200 kb re-
gion of chromosome 12p12.31 commonly over-represented in
both SE and NS (Roelofs et al., 2000; Zafarana et al., 2003). The
overlapping expression patterns of CRIPTO andGDF3 in GCNIS
and the GCC subtypes (Figure 6) suggests that GDF3 (alone, or
in combination with NODAL) could trigger CRIPTO activation.
In this context it is of interest to mention that gain of 12p iscombinations of receptor/ligand expression in normal germ cells,
itive expression (D), negative expression (L) and heterogeneous
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(Rosenberg et al., 2000). It will be interesting to determine
how the specific combinations of CRIPTO/GDF3/NODAL
contribute to the malignancy potential of each subtype, a
question that we are now investigating.
Screening using serum markers is minimally invasive,
rapid and cost-effective. Detection of CRIPTO for diagnostic
and prognostic purposes has been assessed for breast, colon
and brain cancer (Bianco et al., 2006; Pilgaard et al., 2014);
both studies similarly utilized sandwich ELISA for CRIPTO
detection. In our analysis we detected highest average CRIPTO
readings for SE followed by EC, YST then GCNIS-only samples,
of which% sensitivitywas 33%, 40%, 33%, 33% and 80% respec-
tively. Our false positive rate was 6%, however it is possible
that the presence of CRIPTO in this one sample is attributable
to another undetectedmalignancy at the time of serum collec-
tion (CRIPTO is expressed in a wide range of epithelial cancers
(Normanno et al., 2001)). A larger sample size would reduce
the effect such outliers have on the data set. Our background
reading of CRIPTO expression was 0 ng/ml for 14 of 15 control
samples. Conversely, Bianco et al. (2006) detected CRIPTO
levels in plasma of above 0.07 ng/ml for all samples (n ¼ 21)
and Pilgaard et al. (2014) above 0.3 ng/ml for all samples
(n ¼ 27). Discrepancies between our basal levels of CRIPTO
and those from the previous studies can most likely be attrib-
utable to differences in the ELISA assays (Bianco et al., 2006)
and serum dilution factor differences (Bianco et al., 2006;
Pilgaard et al., 2014). We found a 1:2 dilution factor necessary
to consistently achieve good linearity-of-dilution and spike-
and-recovery efficiencies when optimizing our assay (data
not shown). It may be possible to increase the sensitivity of
our assay by increasing the capture and/or detection antibody
concentrations.
An alternative and more promising approach that we are
currently pursuing is detection of CRIPTO using ELISA in
semen samples. As the CRIPTO-expressing GCNIS and GCC
cells are in close proximity with semen, it is feasible that
this will prove highly sensitive for our diagnostic and prog-
nostic purposes. So far, CRIPTO is undetectable in 6/6 controls
(malignancy-free, normozoospermic) in our assay optimized
for semen (data not shown). A great advantage of this
approach, in addition to a likely increase in sensitivity, is
that positivity for CRIPTO in semen would presumably be a
specific indicator of the precursor of GCC, unlike positivity in
serum, as outlined above.
In conclusion, our studies have highlighted regions of the
CRIPTO promoter that appear to be differentially methylated
in fetal germ cells and GCC derived from incorrect germ cell
differentiation. We have also demonstrated for the first time
the potential suitability of CRIPTO as a serological marker
for diagnostic and/or prognostic purposes for GCC. We are
now investigating whether detection in semen may offer an
alternative and potentially more sensitive means for GCC
diagnosis.Disclosure/conflicts of interest
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